Checkpoint Surgical enrolls first patient in study of its nerve-regeneration technology

Checkpoint-Logo-Blue

Checkpoint Surgical Inc., a privately held company in Independence that produces nerve-stimulation medical devices, has hit an important point in the advancement of its nerve regeneration technology.

The company on Wednesday, Jan. 26, announced in a news release that it has enrolled the first patient in its multi-center clinical study of the technology, called the BEST (Brief Electrical Stimulation Therapy) system. The patient was enrolled at Ohio State University, one of four sites enrolling patients in the double-blind, randomized clinical trial.

Click here to read the complete story.

Story excerpt provided by Crain’s Cleveland Business.

Written by Scott Suttell.

Originally published January 26, 2022.

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.

%d bloggers like this: